Nureca Quarterly Results for Trading Insights
In Sept 2025, Nureca (NURECA) reported revenue ₹40 Cr and net profit ₹4 Cr — revenue +17.6% YoY. For annual financials, live price and key ratios, visit Nureca share price chart.
NURECA Quarterly Results — Revenue, Profit & EPS Highlights
Nureca latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore NURECA share price history to track price trends across different timeframes.
- Revenue of ₹40 Cr in Sept 2025 (+17.6% vs Mar 2025, +17.6% vs Sept 2024)
- Net Profit of ₹4 Cr in Sept 2025 (+33.3% vs Mar 2025, +500.0% vs Sept 2024)
- EBITDA of ₹6 Cr in Sept 2025 (+100.0% vs Mar 2025)
- Operating Margin of 9.0% in Sept 2025 (+5.0pp vs Mar 2025)
- Earnings Per Share of ₹3.63 in Sept 2025 (+47.0% vs Mar 2025)
Nureca Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NURECA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 40 | 34 | 37 | 42 | 34 | 17.6% | 17.6% |
| Net Profit (₹ Cr) | 4 | 3 | 1 | 4 | -1 | - | - |
| EBITDA (₹ Cr) | 6 | 3 | 2 | 5 | 1 | - | - |
| EPS (₹) | 3.63 | 2.47 | 0.81 | 3.91 | -0.48 | - | - |
| Operating Margin (%) | 9.0% | 4.0% | -2.0% | 8.0% | -8.0% | - | - |
NURECA Share Price Trend — 1-Year Movement Across Quarterly Results
Nureca 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with NURECA stock valuation models to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NURECA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nureca latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores